Comparable stake leader
BlackRock, Inc.
SEC ownership of ANI PHARMACEUTICALS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001023024.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
18 Jul 2026
- Public ticker
- ANIP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
18 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001023024
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ANI PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
18 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 13%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
13%
Meridian Venture Partners II GP, ...
4.8%
MILLENNIUM MANAGEMENT LLC
3.8%
INTEGRATED CORE STRATEGIES (US) LLC
0.3%
Muthusamy Shanmugam
2.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
13%
|
$240,049,004
2,899,843 shares
|
+$31,656,645 | 30 Jun 2026 |
| Meridian Venture Partners II GP, L.P. |
13D/G
Robert E. Brown, Jr.
|
4.8%
|
$66,419,394
1,034,570 shares
|
-$9,630,000 | 21 Aug 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
3.8%
|
$57,136,569
818,341 shares
|
-$19,037,261 | 31 Mar 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
0.3%
|
$5,976,442
65,245 shares
|
-$96,309,614 | 30 Sep 2025 |
| Muthusamy Shanmugam |
3/4/5
HEAD OF R&D, COO-NOVITIUM OPS, Director
|
2.4%
|
$44,650,672
537,976 shares
|
-$17,860,541 | 26 Feb 2026 |
| Nikhil Lalwani |
3/4/5
PRESIDENT & CEO, Director
|
1.5%
|
$27,140,889
349,889 shares
|
-$9,160,923 | 11 May 2026 |
| Chad Gassert |
3/4/5
SVP - CORP. DEV. & STRATEGY
|
1%
|
$18,904,923
233,406 shares
|
-$3,051,835 | 26 Feb 2026 |
| Christopher Mutz |
3/4/5
HEAD OF RARE DISEASE
|
0.4%
|
$6,541,376
91,309 shares
|
-$1,635,601 | 13 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$49,959,718.
Buys
$0
Insiders: 0
Sells
$49,959,718
Insiders: 15
Net
-$49,959,718
Shares: -583,647
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 583,647
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 88,029 | $0 | $6,954,472 | -$6,954,472 |
| 3-6 | 0 | 53,687 | $0 | $4,046,727 | -$4,046,727 |
| 6-9 | 0 | 28,101 | $0 | $2,453,063 | -$2,453,063 |
| 9-12 | 0 | 413,830 | $0 | $36,505,457 | -$36,505,457 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to ANI PHARMACEUTICALS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
MERIDIAN VENTURE PARTNERS II LP
Net 12M change
-$49,959,720
Latest report
29 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| MERIDIAN VENTURE PARTNERS II LP | 10%+ Owner | $102,678,978 | Mixed | 16 Aug 2023 | ||
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | $44,650,672 | -$17,860,541 | -29% | Mixed | 26 Feb 2026 |
| Nikhil Lalwani | PRESIDENT & CEO, Director | $27,140,889 | -$9,160,923 | -25% | Filing P/S | 11 May 2026 |
| Chad Gassert | Svp Corp. Dev. & Strategy | $18,904,923 | -$3,051,835 | -14% | Mixed | 26 Feb 2026 |
| Stephen P. Carey | Svp & Cfo | $14,213,022 | -$5,877,027 | -29% | Filing P/S | 29 Jul 2026 |
| James G. Marken | Svp Ops & Prod Dev | $7,977,023 | Mixed | 07 Jun 2024 | ||
| Christopher Mutz | Head Of Rare Disease | $6,541,376 | -$1,635,601 | -20% | Filing P/S | 13 Mar 2026 |
| Ori Gutwerg | Svp, Generics | $6,256,332 | -$886,155 | -12% | Filing P/S | 12 May 2026 |
| Meredith W. Cook | Sr. Vp, General Counsel & Sec. | $6,202,208 | -$455,653 | -6.8% | Median | 18 Jul 2026 |
| Krista Davis | Svp, Chief Hr Officer | $3,850,756 | -$1,177,272 | -23% | Filing P/S | 06 Mar 2026 |
| Thomas Haughey | Director | $3,144,452 | -$1,823,732 | -37% | Filing P/S | 21 May 2026 |
| Patrick D. Walsh | Director | $3,098,772 | -$3,124,854 | -50% | Filing P/S | 11 May 2026 |
| Thomas Andrew Rowland | Svp, Head Established Brands | $3,031,445 | -$820,235 | -21% | Filing P/S | 12 May 2026 |
| Robert E. Brown Jr. | Director | $2,766,745 | Mixed | 27 Apr 2022 | ||
| Renee P. Tannenbaum | Director | $2,269,626 | -$146,070 | -6% | Mixed | 21 May 2026 |
| David Nash | Director | $2,176,383 | Mixed | 23 May 2023 | ||
| Jeanne Thoma | Director | $2,134,897 | -$1,920,370 | -47% | Mixed | 21 May 2026 |
| Antonio R. Pera | Director | $2,077,607 | -$1,178,729 | -36% | Mixed | 21 May 2026 |
| Matthew J. Leonard | Director | $862,894 | -$840,723 | -49% | Mixed | 21 May 2026 |
Recent insider transactions for ANI PHARMACEUTICALS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Stephen P. Carey | ANIP | Common Stock | Sale | -1.61% | $231,876 | $81.36 | -2,850 | 174,693 | 29 Jul 2026 | Direct |
| Meredith W. Cook | ANIP | Common Stock | Tax liability | -3.19% | -2,466 | 74,924 | 18 Jul 2026 | Direct | ||
| Meredith W. Cook | ANIP | Common Stock | Sale | -0.64% | $40,920 | $81.84 | -500 | 77,390 | 13 Jul 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Sale | -1.83% | $284,918 | $86.00 | -3,313 | 177,543 | 02 Jul 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Options Exercise | 1.87% | 3,313 | 180,856 | 02 Jul 2026 | Direct | ||
| Stephen P. Carey | ANIP | Stock Option (right to buy) | Options Exercise | -50% | -3,313 | 3,313 | 02 Jul 2026 | Direct | ||
| Stephen P. Carey | ANIP | Common Stock | Sale | -1.58% | $239,742 | $84.12 | -2,850 | 177,543 | 29 Jun 2026 | Direct |
| Meredith W. Cook | ANIP | Common Stock | Sale | -0.64% | $41,015 | $82.03 | -500 | 77,890 | 12 Jun 2026 | Direct |
| Thomas Haughey | ANIP | Common Stock | Sale | -4.89% | $161,760 | $80.88 | -2,000 | 38,878 | 08 Jun 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Sale | -1.8% | $264,960 | $80.00 | -3,312 | 180,393 | 05 Jun 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Options Exercise | 1.84% | 3,312 | 183,705 | 05 Jun 2026 | Direct | ||
| Stephen P. Carey | ANIP | Stock Option (right to buy) | Options Exercise | -33.3% | -3,312 | 6,626 | 05 Jun 2026 | Direct | ||
| Jeanne Thoma | ANIP | Common Stock | Award | 18.6% | 4,357 | 27,762 | 21 May 2026 | Direct | ||
| Renee P. Tannenbaum | ANIP | Common Stock | Award | 17.3% | 4,357 | 29,514 | 21 May 2026 | Direct | ||
| Antonio R. Pera | ANIP | Common Stock | Award | 19.2% | 4,357 | 27,017 | 21 May 2026 | Direct | ||
| Matthew J. Leonard | ANIP | Common Stock | Award | 63.5% | 4,357 | 11,221 | 21 May 2026 | Direct | ||
| Thomas Haughey | ANIP | Common Stock | Award | 11.9% | 4,357 | 40,878 | 21 May 2026 | Direct | ||
| Patrick D. Walsh | ANIP | Common Stock | Sale | -20.6% | $806,300 | $80.63 | -10,000 | 38,432 | 13 May 2026 | Direct |
| Meredith W. Cook | ANIP | Common Stock | Sale | -0.63% | $39,080 | $78.16 | -500 | 78,390 | 13 May 2026 | Direct |
| Thomas Andrew Rowland | ANIP | Common Stock | Sale | -1.19% | $36,357 | $79.21 | -459 | 38,271 | 12 May 2026 | Direct |
| Ori Gutwerg | ANIP | Common Stock | Sale | -3.4% | $220,374 | $79.50 | -2,772 | 78,696 | 12 May 2026 | Direct |
| Patrick D. Walsh | ANIP | Common Stock | Sale | -7.58% | $320,820 | $80.75 | -3,973 | 48,432 | 11 May 2026 | Direct |
| Nikhil Lalwani | ANIP | Common Stock | Sale | -13.6% | $4,266,350 | $77.57 | -55,000 | 349,889 | 11 May 2026 | Direct |
| Meredith W. Cook | ANIP | Common Stock | Sale | -0.63% | $38,975 | $77.95 | -500 | 78,890 | 13 Apr 2026 | Direct |
| Christopher Mutz | ANIP | Common Stock | Sale | -3.35% | $226,526 | $71.64 | -3,162 | 91,309 | 13 Mar 2026 | Direct |
| Meredith W. Cook | ANIP | Common Stock | Sale | -0.63% | $36,310 | $72.62 | -500 | 79,390 | 13 Mar 2026 | Direct |
| Thomas Andrew Rowland | ANIP | Common Stock | Sale | -11% | $357,471 | $74.91 | -4,772 | 38,730 | 11 Mar 2026 | Direct |
| Christopher Mutz | ANIP | Common Stock | Sale | -3.67% | $267,196 | $74.18 | -3,602 | 94,471 | 09 Mar 2026 | Direct |
| Krista Davis | ANIP | Common Stock | Sale | -8.92% | $377,099 | $74.13 | -5,087 | 51,946 | 09 Mar 2026 | Direct |
| Christopher Mutz | ANIP | Common Stock | Tax liability | -3.27% | -3,314 | 98,073 | 07 Mar 2026 | Direct | ||
| Nikhil Lalwani | ANIP | Common Stock | Tax liability | -4.04% | -17,060 | 404,889 | 07 Mar 2026 | Direct | ||
| Ori Gutwerg | ANIP | Common Stock | Tax liability | -3.91% | -3,314 | 81,468 | 07 Mar 2026 | Direct | ||
| Stephen P. Carey | ANIP | Common Stock | Tax liability | -2.78% | -5,150 | 180,393 | 07 Mar 2026 | Direct | ||
| Christopher Mutz | ANIP | Common Stock | Sale | -2.05% | $157,421 | $74.22 | -2,121 | 101,387 | 06 Mar 2026 | Direct |
| Krista Davis | ANIP | Common Stock | Sale | -2.54% | $111,375 | $75.00 | -1,485 | 57,033 | 06 Mar 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Sale | -3.79% | $552,031 | $75.50 | -7,312 | 185,543 | 05 Mar 2026 | Direct |
| Stephen P. Carey | ANIP | Common Stock | Options Exercise | 1.75% | 3,312 | 192,855 | 05 Mar 2026 | Direct | ||
| Stephen P. Carey | ANIP | Stock Option (right to buy) | Options Exercise | -25% | -3,312 | 9,938 | 05 Mar 2026 | Direct | ||
| Ori Gutwerg | ANIP | Common Stock | Sale | -2.37% | $157,590 | $76.50 | -2,060 | 84,782 | 03 Mar 2026 | Direct |
| Patrick D. Walsh | ANIP | Common Stock | Sale | -10.3% | $445,380 | $74.23 | -6,000 | 52,405 | 03 Mar 2026 | Direct |
| Christopher Mutz | ANIP | Common Stock | Sale | -0.4% | $30,858 | $74.00 | -417 | 103,508 | 02 Mar 2026 | Direct |
| Thomas Andrew Rowland | ANIP | Common Stock | Tax liability | -1.42% | -628 | 43,502 | 28 Feb 2026 | Direct | ||
| Christopher Mutz | ANIP | Common Stock | Tax liability | -2.09% | -2,221 | 103,925 | 28 Feb 2026 | Direct | ||
| Nikhil Lalwani | ANIP | Common Stock | Tax liability | -2.81% | -12,217 | 421,949 | 28 Feb 2026 | Direct | ||
| Ori Gutwerg | ANIP | Common Stock | Tax liability | -2.49% | -2,221 | 86,842 | 28 Feb 2026 | Direct | ||
| Chad Gassert | ANIP | Common Stock | Tax liability | -2.88% | -2,221 | 74,916 | 28 Feb 2026 | Direct | ||
| Krista Davis | ANIP | Common Stock | Tax liability | -2.59% | -1,555 | 58,518 | 28 Feb 2026 | Direct | ||
| Meredith W. Cook | ANIP | Common Stock | Tax liability | -1.91% | -1,555 | 79,890 | 28 Feb 2026 | Direct | ||
| Stephen P. Carey | ANIP | Common Stock | Tax liability | -1.44% | -2,773 | 189,543 | 28 Feb 2026 | Direct | ||
| Muthusamy Shanmugam | ANIP | Common Stock | Award | 12.4% | 11,116 | 101,056 | 26 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.